Last reviewed · How we verify
Ad-TD-nsIL12 — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Ad-TD-nsIL12 (Ad-TD-nsIL12) — Capital Medical University.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Ad-TD-nsIL12 TARGET | Ad-TD-nsIL12 | Capital Medical University | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Ad-TD-nsIL12 CI watch — RSS
- Ad-TD-nsIL12 CI watch — Atom
- Ad-TD-nsIL12 CI watch — JSON
- Ad-TD-nsIL12 alone — RSS
Cite this brief
Drug Landscape (2026). Ad-TD-nsIL12 — Competitive Intelligence Brief. https://druglandscape.com/ci/ad-td-nsil12. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab